By Jared Lynch
CERVICAL cancer vaccine developer Ian Frazer is hoping lightning will strike twice with a new drug aimed at quashing another common cancer.
Coridon, the company Professor Frazer founded, yesterday struck a deal with Ohio State University to further develop its Epstein-Barr virus (EBV) project.
EBV is the cause of glandular fever and can trigger a range of cancers, including lymphoma.
The university and Coridon aim to complete animal studies this year.
Professor Frazer said that if the studies were successful, human trials would begin next year and hopefully the drug would be fast-tracked to commercialisation within the next three years.
Read the entire article here.